Skip to main content
AtriCure, Inc. logo

AtriCure, Inc. — Investor Relations & Filings

Ticker · ATRC ISIN · US04963C2098 LEI · 254900B2I6GPHK2EXM59 US Manufacturing
Open in API
Filings indexed 1,189 across all filing types
Latest filing 2019-10-25 Capital/Financing Update
Country US United States of America
Listing US ATRC

About AtriCure, Inc.

https://www.atricure.com

AtriCure, Inc. is a medical device company focused on developing, manufacturing, and selling technologies for the treatment of atrial fibrillation (Afib), management of the left atrial appendage (LAA), and post-operative pain. The company's product portfolio is primarily utilized by cardiothoracic surgeons and electrophysiologists. Key offerings include surgical ablation systems and the AtriClip® LAA Exclusion System, a widely implanted device for LAA management. Additionally, AtriCure provides cryoablation technology, such as the cryoXT™ Probe, which offers a non-opioid approach to pain management following surgical procedures, including amputation.

Recent filings

Filing Released Lang Actions
424B7
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(7) related to the resale registration of common stock shares by selling stockholders following a merger agreement. It includes detailed information about the securities being registered, the registration fee calculation, and the terms of the offering. The document is a formal filing with the SEC concerning a securities offering and resale registration, not a financial report, earnings release, or management discussion. It is not an announcement of a report but the actual registration prospectus supplement document. This type of filing corresponds to a Capital/Financing Update as it relates to securities registration and offering details.
2019-10-25 English
FORM 8-K/A
Regulatory Filings Classification · 95% confidence The document is a Form 8-K/A, which is an amendment to a current report filed under the Securities Exchange Act of 1934. It specifically amends a prior 8-K filing to provide required financial statements and pro forma financial information related to the acquisition of SentreHEART, Inc. The document includes references to audited and unaudited financial statements of the acquired business and pro forma combined financial information. The primary purpose is to update and supplement the original current report with financial data related to the acquisition. This type of filing is best classified as a Regulatory Filing (RNS) because it is an amendment to a current report providing additional financial disclosures, not a full annual or quarterly report, nor a standalone audit report. It is not a report publication announcement since it contains substantive financial information and exhibits. Therefore, the classification is RNS with high confidence.
2019-10-25 English
FORM 4 SUBMISSION
Director's Dealing
2019-09-18 English
FORM 4 SUBMISSION
Director's Dealing
2019-09-16 English
FORM 4 SUBMISSION
Director's Dealing
2019-09-10 English
FORM 4 SUBMISSION
Director's Dealing
2019-08-16 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.